| abstract |
The present invention relates to a pharmaceutical composition for use in a method of treating or preventing α-synuclein disease, the composition comprising a molecule for pharmacologically modulating galectin activity in the mammalian brain. The present invention also relates to a method for treating or preventing α-synuclein disease in a subject that is a mammal, the method comprising administering to the subject a therapeutically effective amount of at least one composition, the composition comprising: Contains molecules that pharmacologically modulate galectin activity in the mammalian brain. |